#$%^&*AU2020201728A120200326.pdf#####ABSTRACT This invention relates to deuterated analogs of etifoxine of Formula I, solvates, prodrugs, and pharmaceutically acceptable salts thereof, as well as to methods for their preparation and use, and to pharmaceutical compositions. x1x HN1IX12 X2 x HN D N O X2 X3 X2 X3 X3 CI 48WO 2016/154039 PCT/US2016/023231 2000 1800 1600 S A 1400 E 1200 1000 -4-Etifoxine -,-Example 1 400 2 004 0 2 4 6 8 10 121 Figure 1: Mean plasma concentration-time profiles of etifoxine and example 1 after a PO dose of 50 mg/kg in male Sprague-Dawley rats